Charles River Laboratories International, Inc. vs Eli Lilly & Co.
CRL vs LLY — side-by-side comparison from reported financials. CRL leads 4, LLY leads 6 of 10 comparable metrics.
Charles River Laboratories International, Inc.
CRL · Healthcare
$301.79+1.27%Strained
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | CRL | LLY |
|---|---|---|
| Price | $301.79 | $1 177.20 |
| Market cap | $14.4B | $1.05T |
| Revenue (TTM) | $4.00B | $79.7B |
| Revenue growth | +0.3% | +31.7% |
| Net margin | -6.0% | 33.5% |
| Free cash flow | $371M | $18.2B |
| Net cash (debt) | ($1.92B) | ($35.2B) |
| 1-year price return | +75.3% | +37.6% |
| P/E | 20.8 | 41.6 |
| P/E vs own history (cheap-side %) | 98% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | -8% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 5 of 10 | 11 of 10 |
| Employees | 19,700 | 50,000 |
Full résumé-style profiles: CRL CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.